Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin - PubMed (original) (raw)
Comment
doi: 10.1586/erp.10.42.
Affiliations
- PMID: 20715914
- DOI: 10.1586/erp.10.42
Free article
Comment
Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin
Talitha I Verhoef et al. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug.
Free article
Abstract
Patients using warfarin for oral anticoagulant therapy need to be frequently monitored because of warfarin's narrow therapeutic range and the large variation in dose requirements among patients. Patients receiving the wrong dose have an increased risk of bleeding or thromboembolic events. The required dose is influenced by environmental factors, such as gender, age, diet and concomitant medication, as well as genetic factors. Pharmacogenetic testing prior to warfarin initiation might improve dosing accuracy and, therefore, safety and efficacy of warfarin treatment. Meckley et al. studied the clinical consequences and costs of genotyping before warfarin treatment. The results of their study suggest that pharmacogenetic-guided dosing of patients initiating warfarin could improve health (quality-adjusted life-years) but at a high cost per quality-adjusted life-year gained. Owing to the inevitable assumptions that have to be made in all cost-effectiveness models, great uncertainty remains regarding the cost-effectiveness of pharmacogenetic-guided warfarin dosing.
Comment on
- A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.
Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. Meckley LM, et al. Pharmacoeconomics. 2010;28(1):61-74. doi: 10.2165/11318240-000000000-00000. Pharmacoeconomics. 2010. PMID: 20014877
Similar articles
- Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.
Chong HY, Saokaew S, Dumrongprat K, Permsuwan U, Wu DB, Sritara P, Chaiyakunapruk N. Chong HY, et al. Thromb Res. 2014 Dec;134(6):1278-84. doi: 10.1016/j.thromres.2014.10.006. Epub 2014 Oct 14. Thromb Res. 2014. PMID: 25456732 - Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
Patrick AR, Avorn J, Choudhry NK. Patrick AR, et al. Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):429-36. doi: 10.1161/CIRCOUTCOMES.108.808592. Epub 2009 Jul 21. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031873 - Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve.
Hemati H, Nosrati M, Hasanzad M, Rahmani P, Fariman S, Sarabi M, Shirvani S, Sadeghipour P, Nikfar S. Hemati H, et al. Iran J Pharm Res. 2024 May 14;23(1):e143898. doi: 10.5812/ijpr-143898. eCollection 2024 Jan-Dec. Iran J Pharm Res. 2024. PMID: 39108643 Free PMC article. - Use of genetic and nongenetic factors in warfarin dosing algorithms.
Wu AH. Wu AH. Pharmacogenomics. 2007 Jul;8(7):851-61. doi: 10.2217/14622416.8.7.851. Pharmacogenomics. 2007. PMID: 18240910 Review. - A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.
Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M; EU-PACT Group. Verhoef TI, et al. Pharmacogenomics. 2010 Jul;11(7):989-1002. doi: 10.2217/pgs.10.74. Pharmacogenomics. 2010. PMID: 20602617 Review.
Cited by
- Implementing genomic medicine in the clinic: the future is here.
Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, Frazer KA, Korf B, Ledbetter DH, Lupski JR, Marsh C, Mrazek D, Murray MF, O'Donnell PH, Rader DJ, Relling MV, Shuldiner AR, Valle D, Weinshilboum R, Green ED, Ginsburg GS. Manolio TA, et al. Genet Med. 2013 Apr;15(4):258-67. doi: 10.1038/gim.2012.157. Epub 2013 Jan 10. Genet Med. 2013. PMID: 23306799 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources